Kareo vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Merged with PatientPop → Tebra 2021; $222M funding; $1B+ valuation; $72M 2023 (Golub); 100K providers; 90M patients; 1,000 employees; practice management/EHR leader
About
Kareo was founded in 2004 by Dan Rodrigues to build purpose-designed practice management and billing software for independent physician practices — a segment underserved by legacy healthcare IT vendors focused on hospital systems. The platform addressed the full administrative workflow of a small medical practice: appointment scheduling, patient registration, insurance eligibility verification, charge capture, medical billing, and accounts receivable management. Kareo also developed an integrated EHR module, making it one of the few vendors to combine clinical documentation and practice management in a cloud-native platform accessible to solo practitioners.\n\nKareo's products included Kareo Billing for RCM, Kareo Clinical for EHR and documentation, and Kareo Engage for patient communication and online reputation management. The platform served primary care, mental health, physical therapy, and chiropractic specialties. Its cloud-based delivery — accessible via browser and mobile without on-premises infrastructure — resonated strongly with independent practices managing lean overhead. A managed RCM service and QuickBooks integration rounded out the offering.\n\nKareo merged with PatientPop, a digital practice growth platform, in 2021 to form Tebra — targeting the full lifecycle of independent practice management from marketing through billing. The combined company has raised $222 million in total funding, achieved a $1 billion+ valuation, and serves over 100,000 providers across 90 million patients. Tebra continues operating the Kareo brand for billing and EHR while integrating PatientPop's digital presence capabilities into a unified independent practice growth platform.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.